Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives
Pharmaceutical patent strategy is often discussed like a binary choice: fight, settle, or walk away.
But the real world is messier—and more expensive.
In a recent DrugPatentWatch piece, the “cut / keep / cash” decision matrix reframes patent portfolios…
